Share Price and Basic Stock Data
Last Updated: November 28, 2025, 7:26 am
| PEG Ratio | -61.56 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarti Drugs Limited operates in the pharmaceuticals sector and reported a market capitalization of ₹4,052 Cr. The company’s revenue trajectory shows a consistent growth pattern over the years, with sales increasing from ₹972 Cr in March 2014 to ₹2,498 Cr in March 2023. However, the fiscal year 2024 saw a decline in revenue to ₹2,267 Cr, followed by a further drop to ₹2,174 Cr in March 2025. Quarterly sales figures for June 2023 to March 2024 indicate fluctuations, with sales peaking at ₹696 Cr in March 2023 but declining to ₹538 Cr by December 2023. The trailing twelve months (TTM) revenue stood at ₹2,237 Cr, reflecting the challenges faced in maintaining consistent sales growth. The operating profit margin (OPM) ranged from 11% to 14% over the past few quarters, with the most recent quarter reporting an OPM of 12%. This suggests a need for Aarti Drugs to enhance operational efficiency amidst fluctuating sales performance.
Profitability and Efficiency Metrics
The profitability metrics of Aarti Drugs reveal a mixed performance, highlighted by a net profit of ₹190 Cr for the latest fiscal year. The company’s net profit margin stood at 7.04% as of March 2025, demonstrating a slight improvement from previous years, although it remains below the industry average. The return on equity (ROE) was recorded at 13%, while the return on capital employed (ROCE) was slightly higher at 13.5%. These figures indicate that while Aarti Drugs is generating returns for its shareholders, there is room for improvement compared to sector standards. The interest coverage ratio (ICR) of 8.46x suggests that the company is comfortably able to meet its interest obligations, indicating strong operational cash flow. However, the cash conversion cycle (CCC) of 127 days raises concerns regarding working capital management, as it indicates a longer duration to convert investments into cash. This inefficiency could impact liquidity if not addressed effectively.
Balance Sheet Strength and Financial Ratios
Aarti Drugs’ balance sheet reflects a conservative approach to leverage, with total borrowings amounting to ₹440 Cr against reserves of ₹1,250 Cr. The debt-to-equity ratio stands at 0.44, indicating a moderate level of debt relative to equity, which is favorable compared to industry norms. The company’s liquidity ratios are also robust, with a current ratio of 1.60 and a quick ratio of 1.03, suggesting that Aarti Drugs is well-positioned to meet its short-term obligations. The book value per share has increased to ₹149.99 as of March 2025, signaling growth in net worth. However, the decline in the interest coverage ratio from previous years to 8.46x raises concerns about the company’s ability to sustainably manage its interest expenses if profitability continues to be volatile. Overall, the financial ratios indicate a relatively stable financial position, but the company must focus on enhancing profitability to further strengthen its balance sheet.
Shareholding Pattern and Investor Confidence
Aarti Drugs has a diverse shareholder structure, with promoters holding 54.72% of the company’s equity as of September 2025. This level of promoter ownership suggests strong management control, which can instill confidence among investors. Foreign institutional investors (FIIs) hold 2.68%, while domestic institutional investors (DIIs) account for 9.90%, indicating a moderate level of institutional interest. The public shareholding stands at 32.70%, reflecting a healthy distribution among retail investors. However, the gradual decline in promoter shareholding from 59.66% in December 2022 to the current level may raise questions about long-term commitment. The number of shareholders decreased from 1,73,283 in December 2022 to 1,52,252 in September 2025, highlighting a potential concern regarding investor confidence and retention. This decline may be indicative of market sentiment towards the company’s performance and future outlook.
Outlook, Risks, and Final Insight
The outlook for Aarti Drugs Limited hinges on its ability to stabilize revenue and enhance profitability. The company faces several risks, including fluctuating sales figures and a relatively high cash conversion cycle, which could impact liquidity. Additionally, the decline in sales for fiscal 2024 and 2025 raises concerns about market demand and competitive pressures. On the upside, Aarti Drugs has a solid balance sheet with low leverage and strong liquidity, providing a cushion against economic downturns. The company could benefit from operational efficiencies and strategic investments in product development to capture market share. If Aarti Drugs can effectively address its profitability challenges and improve cash flow management, it may enhance shareholder value and restore investor confidence in the long run. Overall, while the company has strengths in its financial structure, it must navigate the outlined risks to achieve sustainable growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aarti Drugs Limited
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 164 Cr. | 130 | 247/84.3 | 36.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,467 Cr. | 410 | 479/192 | 92.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.0 Cr. | 28.0 | 29.3/17.0 | 97.7 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,336.40 Cr | 1,175.88 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 551 | 625 | 626 | 696 | 592 | 578 | 538 | 560 | 493 | 543 | 515 | 623 | 521 |
| Expenses | 496 | 555 | 557 | 608 | 520 | 512 | 478 | 490 | 439 | 484 | 454 | 534 | 457 |
| Operating Profit | 55 | 70 | 69 | 89 | 72 | 65 | 60 | 69 | 54 | 60 | 60 | 89 | 64 |
| OPM % | 10% | 11% | 11% | 13% | 12% | 11% | 11% | 12% | 11% | 11% | 12% | 14% | 12% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 11 | 2 | 0 |
| Interest | 7 | 8 | 9 | 8 | 8 | 8 | 7 | 8 | 7 | 7 | 8 | 7 | 7 |
| Depreciation | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Profit before tax | 36 | 50 | 49 | 69 | 53 | 47 | 43 | 50 | 35 | 41 | 52 | 71 | 45 |
| Tax % | 28% | 27% | 25% | 23% | 25% | 26% | 26% | 27% | 23% | 26% | 26% | 13% | -7% |
| Net Profit | 26 | 37 | 37 | 53 | 40 | 35 | 32 | 36 | 27 | 30 | 39 | 61 | 49 |
| EPS in Rs | 2.85 | 3.95 | 3.96 | 5.74 | 4.27 | 3.76 | 3.44 | 3.93 | 2.93 | 3.31 | 4.19 | 6.69 | 5.29 |
Last Updated: August 2, 2025, 12:55 am
Below is a detailed analysis of the quarterly data for Aarti Drugs Limited based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 521.00 Cr.. The value appears to be declining and may need further review. It has decreased from 623.00 Cr. (Mar 2025) to 521.00 Cr., marking a decrease of 102.00 Cr..
- For Expenses, as of Jun 2025, the value is 457.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 534.00 Cr. (Mar 2025) to 457.00 Cr., marking a decrease of 77.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 89.00 Cr. (Mar 2025) to 64.00 Cr., marking a decrease of 25.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 12.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 45.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 45.00 Cr., marking a decrease of 26.00 Cr..
- For Tax %, as of Jun 2025, the value is -7.00%. The value appears to be improving (decreasing) as expected. It has decreased from 13.00% (Mar 2025) to -7.00%, marking a decrease of 20.00%.
- For Net Profit, as of Jun 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 61.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 12.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.29. The value appears to be declining and may need further review. It has decreased from 6.69 (Mar 2025) to 5.29, marking a decrease of 1.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:51 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 972 | 1,087 | 1,076 | 1,089 | 1,140 | 1,454 | 1,635 | 1,915 | 2,251 | 2,498 | 2,267 | 2,174 | 2,237 |
| Expenses | 822 | 915 | 900 | 910 | 955 | 1,252 | 1,387 | 1,511 | 1,930 | 2,212 | 1,998 | 1,908 | 1,949 |
| Operating Profit | 150 | 172 | 176 | 179 | 185 | 203 | 248 | 404 | 321 | 286 | 269 | 265 | 288 |
| OPM % | 15% | 16% | 16% | 16% | 16% | 14% | 15% | 21% | 14% | 11% | 12% | 12% | 13% |
| Other Income | 1 | 1 | 0 | 4 | 1 | 6 | 9 | 7 | 5 | 2 | 4 | 14 | 14 |
| Interest | 37 | 42 | 47 | 38 | 36 | 41 | 36 | 26 | 23 | 36 | 33 | 32 | 28 |
| Depreciation | 28 | 31 | 36 | 37 | 38 | 40 | 47 | 48 | 47 | 47 | 48 | 48 | 50 |
| Profit before tax | 86 | 100 | 93 | 108 | 112 | 128 | 175 | 338 | 256 | 205 | 192 | 199 | 224 |
| Tax % | 28% | 22% | 29% | 30% | 35% | 32% | 22% | 24% | 24% | 25% | 26% | 21% | |
| Net Profit | 62 | 78 | 66 | 75 | 73 | 87 | 136 | 258 | 195 | 153 | 142 | 157 | 190 |
| EPS in Rs | 6.38 | 8.01 | 6.84 | 7.91 | 7.78 | 9.25 | 14.56 | 27.65 | 21.06 | 16.50 | 15.43 | 17.11 | 20.71 |
| Dividend Payout % | 26% | 41% | 25% | 3% | 3% | 3% | 3% | 9% | 5% | 6% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.81% | -15.38% | 13.64% | -2.67% | 19.18% | 56.32% | 89.71% | -24.42% | -21.54% | -7.19% | 10.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.19% | 29.02% | -16.30% | 21.84% | 37.14% | 33.38% | -114.12% | 2.88% | 14.35% | 17.75% |
Aarti Drugs Limited has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 4% |
| 3 Years: | -7% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -8% |
| 3 Years: | 3% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 18% |
| 3 Years: | 13% |
| Last Year: | 13% |
Last Updated: September 4, 2025, 10:00 pm
Balance Sheet
Last Updated: November 9, 2025, 1:33 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 | 91 |
| Reserves | 239 | 279 | 326 | 363 | 410 | 495 | 598 | 766 | 880 | 1,022 | 1,083 | 1,160 | 1,250 |
| Borrowings | 342 | 435 | 465 | 448 | 517 | 471 | 378 | 336 | 519 | 535 | 475 | 516 | 440 |
| Other Liabilities | 257 | 228 | 240 | 281 | 366 | 384 | 471 | 442 | 543 | 546 | 522 | 506 | 463 |
| Total Liabilities | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
| Fixed Assets | 373 | 431 | 463 | 542 | 564 | 586 | 612 | 631 | 649 | 634 | 722 | 761 | 970 |
| CWIP | 8 | 13 | 34 | 14 | 28 | 32 | 11 | 16 | 60 | 161 | 222 | 273 | 92 |
| Investments | 5 | 11 | 11 | 18 | 17 | 19 | 20 | 24 | 28 | 29 | 30 | 42 | 53 |
| Other Assets | 464 | 511 | 547 | 541 | 707 | 736 | 828 | 966 | 1,297 | 1,372 | 1,198 | 1,196 | 1,130 |
| Total Assets | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
Below is a detailed analysis of the balance sheet data for Aarti Drugs Limited based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,250.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,160.00 Cr. (Mar 2025) to 1,250.00 Cr., marking an increase of 90.00 Cr..
- For Borrowings, as of Sep 2025, the value is 440.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 516.00 Cr. (Mar 2025) to 440.00 Cr., marking a decrease of 76.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 463.00 Cr.. The value appears to be improving (decreasing). It has decreased from 506.00 Cr. (Mar 2025) to 463.00 Cr., marking a decrease of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 970.00 Cr.. The value appears strong and on an upward trend. It has increased from 761.00 Cr. (Mar 2025) to 970.00 Cr., marking an increase of 209.00 Cr..
- For CWIP, as of Sep 2025, the value is 92.00 Cr.. The value appears to be declining and may need further review. It has decreased from 273.00 Cr. (Mar 2025) to 92.00 Cr., marking a decrease of 181.00 Cr..
- For Investments, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 11.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,130.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,196.00 Cr. (Mar 2025) to 1,130.00 Cr., marking a decrease of 66.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
Notably, the Reserves (1,250.00 Cr.) exceed the Borrowings (440.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -192.00 | -263.00 | -289.00 | -269.00 | -332.00 | -268.00 | -130.00 | 68.00 | -198.00 | -249.00 | -206.00 | -251.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 103 | 109 | 93 | 117 | 110 | 104 | 96 | 115 | 117 | 104 | 118 |
| Inventory Days | 71 | 77 | 87 | 101 | 132 | 86 | 107 | 125 | 120 | 102 | 107 | 106 |
| Days Payable | 84 | 75 | 85 | 91 | 125 | 86 | 110 | 94 | 103 | 89 | 96 | 97 |
| Cash Conversion Cycle | 91 | 105 | 110 | 103 | 124 | 109 | 101 | 127 | 133 | 130 | 115 | 127 |
| Working Capital Days | -10 | 13 | 21 | 26 | 33 | 46 | 60 | 83 | 68 | 73 | 79 | 79 |
| ROCE % | 22% | 21% | 18% | 17% | 17% | 17% | 20% | 33% | 21% | 15% | 14% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 4,636,377 | 1.63 | 270.21 | 4,636,377 | 2025-04-22 17:25:44 | 0% |
| DSP Healthcare Fund | 737,671 | 1.47 | 42.99 | 737,671 | 2025-04-22 17:25:44 | 0% |
| Motilal Oswal BSE Healthcare ETF | 460 | 0.15 | 0.03 | 460 | 2025-04-22 17:25:44 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Diluted EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Cash EPS (Rs.) | 24.53 | 24.26 | 23.40 | 27.54 | 35.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Revenue From Operations / Share (Rs.) | 261.54 | 275.04 | 293.31 | 268.75 | 231.20 |
| PBDIT / Share (Rs.) | 33.24 | 34.86 | 33.24 | 36.80 | 47.38 |
| PBIT / Share (Rs.) | 27.13 | 29.26 | 27.81 | 31.39 | 42.03 |
| PBT / Share (Rs.) | 23.20 | 25.62 | 24.21 | 29.15 | 39.59 |
| Net Profit / Share (Rs.) | 18.42 | 18.66 | 17.97 | 22.14 | 30.09 |
| NP After MI And SOA / Share (Rs.) | 18.42 | 18.65 | 17.96 | 22.14 | 30.09 |
| PBDIT Margin (%) | 12.71 | 12.67 | 11.33 | 13.69 | 20.49 |
| PBIT Margin (%) | 10.37 | 10.64 | 9.47 | 11.68 | 18.18 |
| PBT Margin (%) | 8.87 | 9.31 | 8.25 | 10.84 | 17.12 |
| Net Profit Margin (%) | 7.04 | 6.78 | 6.12 | 8.23 | 13.01 |
| NP After MI And SOA Margin (%) | 7.04 | 6.77 | 6.12 | 8.23 | 13.01 |
| Return on Networth / Equity (%) | 12.28 | 13.37 | 13.94 | 19.78 | 30.69 |
| Return on Capital Employeed (%) | 14.25 | 16.43 | 17.29 | 22.92 | 33.46 |
| Return On Assets (%) | 6.53 | 7.04 | 6.86 | 9.28 | 15.87 |
| Long Term Debt / Equity (X) | 0.20 | 0.21 | 0.17 | 0.13 | 0.16 |
| Total Debt / Equity (X) | 0.44 | 0.43 | 0.50 | 0.51 | 0.33 |
| Asset Turnover Ratio (%) | 0.95 | 1.04 | 1.17 | 1.18 | 1.19 |
| Current Ratio (X) | 1.60 | 1.66 | 1.60 | 1.48 | 1.77 |
| Quick Ratio (X) | 1.03 | 1.05 | 1.05 | 0.92 | 1.08 |
| Inventory Turnover Ratio (X) | 4.98 | 3.14 | 3.39 | 3.37 | 3.15 |
| Dividend Payout Ratio (NP) (%) | 5.42 | 5.36 | 5.56 | 4.51 | 8.30 |
| Dividend Payout Ratio (CP) (%) | 4.07 | 4.12 | 4.27 | 3.63 | 7.05 |
| Earning Retention Ratio (%) | 94.58 | 94.64 | 94.44 | 95.49 | 91.70 |
| Cash Earning Retention Ratio (%) | 95.93 | 95.88 | 95.73 | 96.37 | 92.95 |
| Interest Coverage Ratio (X) | 8.46 | 9.56 | 9.25 | 16.42 | 19.24 |
| Interest Coverage Ratio (Post Tax) (X) | 5.69 | 6.12 | 6.00 | 10.88 | 13.20 |
| Enterprise Value (Cr.) | 3706.38 | 4541.99 | 3725.82 | 4488.49 | 6770.51 |
| EV / Net Operating Revenue (X) | 1.55 | 1.80 | 1.37 | 1.80 | 3.14 |
| EV / EBITDA (X) | 12.22 | 14.17 | 12.10 | 13.17 | 15.33 |
| MarketCap / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| Retention Ratios (%) | 94.57 | 94.63 | 94.43 | 95.48 | 91.69 |
| Price / BV (X) | 2.27 | 3.11 | 2.62 | 3.83 | 7.09 |
| Price / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| EarningsYield | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 |
After reviewing the key financial ratios for Aarti Drugs Limited, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.53. This value is within the healthy range. It has increased from 24.26 (Mar 24) to 24.53, marking an increase of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 261.54. It has decreased from 275.04 (Mar 24) to 261.54, marking a decrease of 13.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 33.24. This value is within the healthy range. It has decreased from 34.86 (Mar 24) to 33.24, marking a decrease of 1.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 27.13. This value is within the healthy range. It has decreased from 29.26 (Mar 24) to 27.13, marking a decrease of 2.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.20. This value is within the healthy range. It has decreased from 25.62 (Mar 24) to 23.20, marking a decrease of 2.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.66 (Mar 24) to 18.42, marking a decrease of 0.24.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.65 (Mar 24) to 18.42, marking a decrease of 0.23.
- For PBDIT Margin (%), as of Mar 25, the value is 12.71. This value is within the healthy range. It has increased from 12.67 (Mar 24) to 12.71, marking an increase of 0.04.
- For PBIT Margin (%), as of Mar 25, the value is 10.37. This value is within the healthy range. It has decreased from 10.64 (Mar 24) to 10.37, marking a decrease of 0.27.
- For PBT Margin (%), as of Mar 25, the value is 8.87. This value is below the healthy minimum of 10. It has decreased from 9.31 (Mar 24) to 8.87, marking a decrease of 0.44.
- For Net Profit Margin (%), as of Mar 25, the value is 7.04. This value is within the healthy range. It has increased from 6.78 (Mar 24) to 7.04, marking an increase of 0.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.04. This value is below the healthy minimum of 8. It has increased from 6.77 (Mar 24) to 7.04, marking an increase of 0.27.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.28. This value is below the healthy minimum of 15. It has decreased from 13.37 (Mar 24) to 12.28, marking a decrease of 1.09.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.25. This value is within the healthy range. It has decreased from 16.43 (Mar 24) to 14.25, marking a decrease of 2.18.
- For Return On Assets (%), as of Mar 25, the value is 6.53. This value is within the healthy range. It has decreased from 7.04 (Mar 24) to 6.53, marking a decrease of 0.51.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.20, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 0.44, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.95. It has decreased from 1.04 (Mar 24) to 0.95, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.60. This value is within the healthy range. It has decreased from 1.66 (Mar 24) to 1.60, marking a decrease of 0.06.
- For Quick Ratio (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 1.05 (Mar 24) to 1.03, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.98. This value is within the healthy range. It has increased from 3.14 (Mar 24) to 4.98, marking an increase of 1.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.42. This value is below the healthy minimum of 20. It has increased from 5.36 (Mar 24) to 5.42, marking an increase of 0.06.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.07. This value is below the healthy minimum of 20. It has decreased from 4.12 (Mar 24) to 4.07, marking a decrease of 0.05.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.58. This value exceeds the healthy maximum of 70. It has decreased from 94.64 (Mar 24) to 94.58, marking a decrease of 0.06.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.93. This value exceeds the healthy maximum of 70. It has increased from 95.88 (Mar 24) to 95.93, marking an increase of 0.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 9.56 (Mar 24) to 8.46, marking a decrease of 1.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.69. This value is within the healthy range. It has decreased from 6.12 (Mar 24) to 5.69, marking a decrease of 0.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,706.38. It has decreased from 4,541.99 (Mar 24) to 3,706.38, marking a decrease of 835.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has decreased from 1.80 (Mar 24) to 1.55, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 12.22. This value is within the healthy range. It has decreased from 14.17 (Mar 24) to 12.22, marking a decrease of 1.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 94.57. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.57, marking a decrease of 0.06.
- For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 3.11 (Mar 24) to 2.27, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Drugs Limited:
- Net Profit Margin: 7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.25% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.28% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.03
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.6 (Industry average Stock P/E: 52.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 198, M.I.D.C., Palghar District Maharashtra 401506 | investorrelations@aartidrugs.com http://www.aartidrugs.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant V Gogri | Chairman Emeritus |
| Mr. Prakash M Patil | Chairman & M.D & CEO |
| Mr. Rashesh C Gogri | Managing Director |
| Mr. Harshit M Savla | Joint Managing Director |
| Mr. Harit P Shah | Executive Director |
| Mr. Uday M Patil | Executive Director |
| Mr. Narendra J Salvi | Non Executive Director |
| Mr. Ankit V Paleja | Independent Director |
| Prof. Bhaskar N Thorat | Independent Director |
| Mrs. Neha R Gada | Independent Director |
| Mr. Hasmukh B Dedhia | Independent Director |
| Mr. Sandeep M Joshi | Independent Director |
| Mr. Ajit E Venugopalan | Independent Director |
FAQ
What is the intrinsic value of Aarti Drugs Limited?
Aarti Drugs Limited's intrinsic value (as of 28 November 2025) is 315.66 which is 26.59% lower the current market price of 430.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,921 Cr. market cap, FY2025-2026 high/low of 575/312, reserves of ₹1,250 Cr, and liabilities of 2,245 Cr.
What is the Market Cap of Aarti Drugs Limited?
The Market Cap of Aarti Drugs Limited is 3,921 Cr..
What is the current Stock Price of Aarti Drugs Limited as on 28 November 2025?
The current stock price of Aarti Drugs Limited as on 28 November 2025 is 430.
What is the High / Low of Aarti Drugs Limited stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Drugs Limited stocks is 575/312.
What is the Stock P/E of Aarti Drugs Limited?
The Stock P/E of Aarti Drugs Limited is 20.6.
What is the Book Value of Aarti Drugs Limited?
The Book Value of Aarti Drugs Limited is 147.
What is the Dividend Yield of Aarti Drugs Limited?
The Dividend Yield of Aarti Drugs Limited is 0.23 %.
What is the ROCE of Aarti Drugs Limited?
The ROCE of Aarti Drugs Limited is 13.5 %.
What is the ROE of Aarti Drugs Limited?
The ROE of Aarti Drugs Limited is 13.0 %.
What is the Face Value of Aarti Drugs Limited?
The Face Value of Aarti Drugs Limited is 10.0.